Premarin for Alzheimer's Phase II trial to begin in autumn under auspices of NIA.
Executive Summary
PREMARIN FOR ALZHEIMER's PHASE II STUDY TO BEGIN IN LATE AUTUMN in a National Institute on Aging- sponsored trial examining the use of Wyeth-Ayerst's conjugated estrogens product to treat the loss of cognitive function associated with Alzheimer's disease. Under the supervision of project director Ruth Mulnard, University of California-Irvine, the study will test whether estrogen replacement therapy can improve or stabilize cognitive function in hysterectomized, postmenopausal women with dementia.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: